Accepted for Publication: May 31, 2019.
Corresponding Authors: S. Claiborne Johnston, MD, PhD, Dean’s Office, Dell Medical School, University of Texas at Austin, 1912 Speedway, Ste 564, Austin, TX 78712 (clay.johnston@utexas.edu) and Yongjun Wang, MD, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, South 4th Ring West Road, Fengtai District, Beijing, China, 100070 (yongjunwang@ncrcnd.org.cn).
Published Online: August 19, 2019. doi:10.1001/jamaneurol.2019.2531
Correction: This article was corrected on September 30, 2019, to fix an error in Figure 2 . The labels “major ischemic events” (for the black line) and “major hemorrhages” (for the orange line) were missing from Figure 2 and have been added. This article was corrected online.
Author Contributions: Drs Johnston and Yongjun Wang had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Pan and Elm contributed equally to this work as co–first authors.
Concept and design: Li, Farrant, Kim, Liu, Yongjun Wang, Johnston.
Acquisition, analysis, or interpretation of data: Pan, Elm, Li, Easton, Yilong Wang, Meng, Kim, Zhao, Meurer, Dietrich, Johnston.
Drafting of the manuscript: Pan, Farrant, Liu, Johnston.
Critical revision of the manuscript for important intellectual content: Elm, Li, Easton, Yilong Wang, Farrant, Meng, Kim, Zhao, Meurer, Dietrich, Yongjun Wang.
Statistical analysis: Pan, Elm.
Obtained funding: Easton, Yongjun Wang, Johnston.
Administrative, technical, or material support: Yilong Wang, Farrant, Meng, Zhao, Johnston.
Supervision: Li, Yilong Wang, Zhao, Liu, Yongjun Wang, Johnston.
Conflict of Interest Disclosures: Dr Elm reports grants from the National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Easton reports grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, nonfinancial support from Sanofi, and personal fees from Boehringer Ingelheim during the conduct of the study. Dr Kim reports grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke during the conduct of the study, as well as personal fees from Neuravi and grants from SanBio outside the submitted work. Dr Meurer reports grants from the National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Johnston reports grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, with Sanofi providing drug and matching placebo for 85% of the patients enrolled in the trial, nonfinancial support from Sanofi, and grants from AstraZeneca during the conduct of the study. No other disclosures were reported.
Funding/Support: The study is supported by grants from Ministry of Science and Technology of the People’s Republic of China (grants 2016YFC0901001, 2016YFC0901002, 2017YFC1310901, 2017YFC1310902, 2017YFC1307905, 2018YFC1311700, and 2018YFC1311706), Beijing Municipal Commission of Health and Family Planning (grants 2016-1-2041 and SML20150502), Beijing Municipal Science & Technology Commission (grant D151100002015003), the National Institute of Neurological Disorders and Stroke (grants U01 NS062835, U01 NS056975, and U01NS059041), and Sanofi.
Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: This investigator-initiated pooled analysis was supported by Sanofi. The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development and presentation of this publication.
2.Johnston
SC, Easton
JD, Farrant
M,
et al; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
N Engl J Med. 2018;379(3):215-225. doi:
10.1056/NEJMoa1800410PubMedGoogle ScholarCrossref 5.Hao
Q, Tampi
M, O’Donnell
M, Foroutan
F, Siemieniuk
RA, Guyatt
G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
BMJ. 2018;363:k5108. doi:
10.1136/bmj.k5108PubMedGoogle ScholarCrossref 7.Kim
JT, Park
MS, Choi
KH,
et al. Comparative effectiveness of aspirin and clopidogrel versus aspirin in acute minor stroke or transient ischemic attack.
Stroke. 2018;50(1):A118022691.
PubMedGoogle Scholar 8.Kennedy
J, Hill
MD, Ryckborst
KJ, Eliasziw
M, Demchuk
AM, Buchan
AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Lancet Neurol. 2007;6(11):961-969. doi:
10.1016/S1474-4422(07)70250-8PubMedGoogle ScholarCrossref 10.Powers
WJ, Rabinstein
AA, Ackerson
T,
et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke. 2018;49(3):e46-e110. doi:
10.1161/STR.0000000000000158PubMedGoogle ScholarCrossref 11.Boulanger
JM, Lindsay
MP, Gubitz
G,
et al. Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th Edition, update 2018.
Int J Stroke. 2018;13(9):949-984. doi:
10.1177/1747493018786616PubMedGoogle ScholarCrossref 14.Prasad
K, Siemieniuk
R, Hao
Q,
et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
BMJ. 2018;363:k5130. doi:
10.1136/bmj.k5130PubMedGoogle ScholarCrossref 17.Yang
Y, Zhou
M, Zhong
X,
et al. Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis.
Stroke Vasc Neurol. 2018;3(2):107-116. doi:
10.1136/svn-2018-000168PubMedGoogle ScholarCrossref 20.Benavente
OR, Hart
RG, McClure
LA, Szychowski
JM, Coffey
CS, Pearce
LA; SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
N Engl J Med. 2012;367(9):817-825. doi:
10.1056/NEJMoa1204133PubMedGoogle ScholarCrossref